MYR Pharmaceuticals Announces Presentation of Final Results of the MYR203 Study of bulevirtide (Myrcludex) at the International Liver Congress (ILC) 2019 in Vienna.

BURGWEDEL, Germany, April 4, 2019 /PRNewswire/ -- MYR Pharmaceuticals today announced that the final results of the MYR203 study of bulevirtide (Myrcludex), MYR's first-in-class entry inhibitor for treatment of hepatitis B and D infection, will be presented at the General Session of the upcoming 2019 ILC meeting in Vienna:

• Heiner Wedemeyer, "Final results of a multicenter, open-label Phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with PEG-interferon alpha 2a in patients with chronic HBV/HDV co-infection ", General Session III, April 13, 10:00 am.

The final results of the MYR203 study have been selected as one of the most exciting abstracts submitted to the 2019 ILC congress. In the course of the official ILC Press Conference "New Therapeutic Approaches" on Friday 12^th April from 10:30 to 11:30, Prof. H. Wedemeyer will present the main findings of the MYR203 study.

An additional presentation will be given at the 17^th Hepatitis Delta International Network (HDIN) Meeting during 2019 ILC:

• Alexander Alexandrov, "Myrcludex (bulevirtide), a First-in-class Entry Inhibitor for Treatment of HBV/HDV Infection: Overview of the Clinical Development Status", EASL Congress venue, Lehar 2, April 10, 19:00pm

"I am contended and very enthusiastic to see how the HBV/HDV entry inhibitor bulevirtide (Myrcludex), developed in my laboratory, has now reached patients in need showing compelling antiviral activity in all clinical trials. The exiting data of the MYR203 trial presented during the ILC meeting 2019 will provide new clinical insights how monotherapy with bulevirtide (Myrcludex) and IFN add-on treatment helps patients suffering from chronic hepatitis delta. Moreover, this trial will guide us to combination therapies for future curative regimens for HDV and HBV," said Stephan Urban, Professor for Translational Virology at Heidelberg University Hospital and inventor of bulevirtide (Myrcludex).

MYR Pharmaceuticals will be present with a scientific corner in Hall B, booth number 450. Visit MYR Pharmaceuticals during the upcoming ILC meeting from 11 April to 13 April in Vienna, Austria, and arrange your personal appointment with our experts on site now.

About bulevirtide (Myrcludex)
Bulevirtide (Myrcludex) is a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug inhibits the NTCP receptor on the hepatocyte surface and prevents the infection of healthy cells and viral spreading within the liver. Bulevirtide has received Orphan Drug Designation for treatment of HDV infection from the European Medicines Agency (EMA) and from the U.S. Food & Drug Administration (FDA). In addition, the EMA has granted PRIority MEdicines (PRIME) scheme eligibility - by this designation EMA offers early and proactive support for the development of medicines that target an unmet medical need.  In parallel the FDA has granted Breakthrough Therapy designation - a process designed to expedite the development and review of drugs which may demonstrate substantial improvements on a clinically significant endpoint. The British Medicines and Healthcare products Regulatory Agency (MHRA) has recently issued the Promising Innovative Medicine (PIM) designation for MYR's lead compound bulevirtide (Myrcludex).

About MYR Pharmaceuticals
MYR Pharmaceuticals is a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D virus infections. The company's lead compound is currently progressing into Phase 3 studies in the indication of chronic HDV infection.

Contact Details
Thomas Christély
Phone: +49 (0)6172-4959811
Email: [email protected]

SOURCE MYR Pharmaceuticals